Business
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and
About this update from Kala Bio, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nKala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.\n\nThe dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 5865513. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.\n\nAbout Kala Pharmaceuticals, Inc.\n\nKala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210218005128/en/\n\nInvestor Contact:\nHannah Deresiewicz\[email protected]\n212-362-1200\n\nSource: Kala Pharmaceuticals, Inc.","length":3186,"tagName":"div"}]